Y L Kasamon

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Management of symptomatic, untreated chronic lymphocytic leukemia
    Yvette L Kasamon
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood Rev 21:143-56. 2007
  2. ncbi request reprint Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia
    Yvette L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Clin Cancer Res 11:8413-7. 2005
  3. pmc FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma
    Yvette L Kasamon
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA
    Curr Opin Oncol 20:206-19. 2008
  4. pmc Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography
    Yvette L Kasamon
    Department of Oncology and Medicine, Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA
    Adv Hematol 2011:271595. 2011
  5. pmc Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas
    Yvette L Kasamon
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 17:365-73. 2011
  6. pmc Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome
    Yvette L Kasamon
    Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 16:482-9. 2010
  7. pmc Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma
    Y L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Ann Oncol 21:1203-10. 2010
  8. pmc Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning
    Yvette L Kasamon
    Johns Hopkins University, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 15:242-8. 2009
  9. ncbi request reprint Immunotherapies for Hodgkin's lymphoma
    Yvette L Kasamon
    Division of Hematologic Malignancies, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Crit Rev Oncol Hematol 66:135-44. 2008
  10. ncbi request reprint Blood or marrow transplantation for mantle cell lymphoma
    Yvette L Kasamon
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Curr Opin Oncol 19:128-35. 2007

Detail Information

Publications20

  1. ncbi request reprint Management of symptomatic, untreated chronic lymphocytic leukemia
    Yvette L Kasamon
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood Rev 21:143-56. 2007
    ..Examples of possible treatment algorithms based on risk category are explored. How to tailor treatment based on these newer prognostic factors remains a central, as yet unanswered management question...
  2. ncbi request reprint Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia
    Yvette L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Clin Cancer Res 11:8413-7. 2005
    ....
  3. pmc FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma
    Yvette L Kasamon
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA
    Curr Opin Oncol 20:206-19. 2008
    ..Outcomes based on midtreatment FDG PET performed during primary and salvage therapy are reviewed and management strategies considered, with a focus on treatment intensification for poor-risk disease as identified by metabolic imaging...
  4. pmc Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography
    Yvette L Kasamon
    Department of Oncology and Medicine, Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA
    Adv Hematol 2011:271595. 2011
    ..How to tailor treatment on the basis of the interim PET result is not yet defined but is the subject of ongoing trials...
  5. pmc Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas
    Yvette L Kasamon
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 17:365-73. 2011
    ..Thus, 4-HC-purged ABMT can produce extended remissions in a subgroup of patients with indolent lymphomas...
  6. pmc Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome
    Yvette L Kasamon
    Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 16:482-9. 2010
    ..55, P = .03 for 3-4 vs fewer allele mismatches). Thus, greater HLA disparity does not appear to worsen overall outcome after NMA haploidentical BMT with high-dose posttransplantation cyclophosphamide...
  7. pmc Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma
    Y L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Ann Oncol 21:1203-10. 2010
    ..Rituximab may improve transplant outcomes but may delay immunologic recovery...
  8. pmc Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning
    Yvette L Kasamon
    Johns Hopkins University, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 15:242-8. 2009
    ..The favorable outcome achieved here in historically poor-risk patients warrants further, more definitive investigation of treatment modification based on early PET scanning...
  9. ncbi request reprint Immunotherapies for Hodgkin's lymphoma
    Yvette L Kasamon
    Division of Hematologic Malignancies, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Crit Rev Oncol Hematol 66:135-44. 2008
    ..The clinical experience with adoptive immunotherapy of Epstein-Barr virus positive tumors, and with monoclonal antibodies directed against CD30, CD20, and other antigens, is herein reviewed...
  10. ncbi request reprint Blood or marrow transplantation for mantle cell lymphoma
    Yvette L Kasamon
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Curr Opin Oncol 19:128-35. 2007
    ..Mantle cell lymphoma is a generally incurable disease for which blood or marrow transplantation is frequently considered. This review assesses the more recent literature on high-dose therapeutic approaches for mantle cell lymphoma...
  11. pmc Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen
    J Bolanos-Meade
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Bone Marrow Transplant 43:477-80. 2009
    ..The combination of fludarabine and alemtuzumab is an effective and well-tolerated salvage conditioning regimen for patients who experience graft failure after blood or marrow transplants...
  12. ncbi request reprint High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement
    Yvette L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 11:93-100. 2005
    ..These data suggest that patients with lymphomatous involvement of the CNS who achieve CNS remission should be offered BMT if it is otherwise indicated...
  13. pmc Circulating clonotypic B cells in classic Hodgkin lymphoma
    Richard J Jones
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Blood 113:5920-6. 2009
    ..Although the clinical significance of circulating clonotypic B cells in HL remains unclear, these data suggest they may be the initiating cells for HL...
  14. pmc Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma
    Javier BolaƱos-Meade
    George W Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 13:1185-91. 2007
    ..The administration of oral cyclosporine followed by interleukin-2 and gamma-interferon is generally not well tolerated, and does not appear to be an effective method to induce autologous GVHD in patients receiving autologous PBSC grafts...
  15. pmc K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate
    B Douglas Smith
    Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and St Agnes Hospital, Baltimore, Maryland 21231, USA
    Clin Cancer Res 16:338-47. 2010
    ..A pilot study was developed to determine if K562/GM-CSF immunotherapy could improve clinical responses to imatinib mesylate (IM) in patients with chronic myeloid leukemia...
  16. ncbi request reprint FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy
    Yvette L Kasamon
    Divisions of Hematologic Malignancies and Nuclear Medicine, Johns Hopkins Medical Institutions, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 207, Baltimore, MD 21231, USA
    Curr Opin Oncol 16:100-5. 2004
    ..This review summarizes the developments in risk assessment through positron emission tomography in patients with lymphoma and the implications for management...
  17. ncbi request reprint Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma
    Yvette L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 11:39-46. 2005
    ..Whether allogeneic BMT ultimately confers an advantage because of a graft-versus-lymphoma effect remains to be determined...
  18. ncbi request reprint Integrating PET and PET/CT into the risk-adapted therapy of lymphoma
    Yvette L Kasamon
    Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Nucl Med 48:19S-27S. 2007
    ..We selected aggressive lymphomas as a platform for the discussion of these imaging modalities in oncology patients and the resulting management questions...
  19. ncbi request reprint MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma
    Tomohide Tatsumi
    Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Clin Cancer Res 9:947-54. 2003
    ..These data suggest that MAGE-6-derived epitopes could serve as useful vaccine candidate components and may provide an immune-monitoring index of clinically important Th1-type immunity in patients with renal cell carcinoma or melanoma...
  20. ncbi request reprint EBV-associated lymphoma and chronic inflammatory demyelinating polyneuropathy in an adult without overt immunodeficiency
    Yvette L Kasamon
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Hematol 69:289-93. 2002
    ..EBV-associated lymphoproliferative disease can thus develop in the absence of overt immunodeficiency and may trigger a demyelinating polyneuropathy...